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Estimates of the prevalence of drug usage during pregnancy vary by region and survey tool used. Clinicians providing care to
newborns should be equipped to recognize a newborn who has been exposed to illicit drugs during pregnancy by the eﬀects the
exposure might cause at the time of delivery and/or by drug testing of the newborn. The purpose of this paper is to provide an
overview of the literature and assess the clinical role of drug testing in the newborn. Accurate recognition of a newborn whose
mother has used illicit drugs in pregnancy cannot only impact decisions for healthcare in the nursery around the time of delivery,
butcanalsoprovideakeyopportunitytoassessthemotherforneededservices.Whiledruguseinpregnancyisnotanindependent
predictor of the mother’s ability to provide a safe and nurturing environment for her newborn, other issues that often cooccur in
the life of a mother with a substance abuse disorder raise concerns for the safety of the discharge environment and should be
assessed. Healthcare providers in these roles should advocate for unbiased and eﬀective treatment services for aﬀected families.
1.Introduction
Estimates of illicit drug use in pregnancy vary widely. Ap-
proximately 5–10% of women self-report the use of illicit
drugs in pregnancy [1–3], while universal testing for illicit
drugs in high-risk populations results in a signiﬁcantly high-
er prevalence (10–40%) of usage than through self-reporting
[2, 3]. There is a wide range of use varying from infrequent
recreational use to high levels of use with physiologic addic-
tion. Importantly, other substances that can have deleterious
eﬀectsonthemotherandinfantshealth(suchasnicotineand
alcohol) are often used concurrently with illicit drugs [1].
Identiﬁcation of newborns exposed to illicit drugs in
pregnancycannotonlyalertthepractitionertoproblemsone
might encounter in the delivery room and nursery, but can
also serve as an opportunity to recognize and assess families
with substance abuse disorders which can pose risks to the
newbornafterhospitaldischarge.However,sinceself-reports
of illicit drug use are often inaccurate and universal drug
testingisneitherpracticalforthecliniciannorrecommended
bytheAmericanAcademyofPediatrics[4],everyfacilitythat
providescarefornewbornsshouldestablishtheirowntesting
protocol including establishing unbiased guidelines to iden-
tify those to be tested. Policies should be in place allowing
for conﬁrmation of test results that have been performed by
screening methods which provide only presumptive results.
2. Possible Effects on Neonates due to
IllicitDrugUse inPregnancy
The short- and long-term adverse eﬀects encountered by
newborns exposed to illicit drugs in pregnancy can be dif-
ﬁcult to accurately assess. In utero exposure to alcohol and
nicotine has established potentials for negative eﬀects on the
newborn such as impairments in growth and later cognition
[5]. While these substances are often used in conjunction
with illicit drugs, they are rarely included in newborn2 International Journal of Pediatrics
screening or reporting policies [6]. As a result, studies ex-
amining the health eﬀects of newborns exposed to illicit
drugs in pregnancy can be confounded by the presence of
other nonillicit substances whose presence can be diﬃcult to
control for in study design (especially if relying on self-re-
ported usage). In utero exposure to alcohol and nicotine are
the premier confounders. Also, eﬀects attributed to illicit
substance exposure during pregnancy may be confounded
by the problems associated with substance abuse disorders
such as poor nutrition, overall health status, and attendance
at prenatal visits [7–9].
Table 1 provides a summary of possible adverse eﬀects
associated with exposure to the most commonly encounter-
ed illicit drugs (stimulants, cannabinoids, opiates/opioids,
hallucinogens, and sedatives). While cocaine and metham-
phetamine both behave pharmacologically as stimulants (in-
creased arousal, vasoconstriction, elevated heart rate, and
blood pressure), much of the information about long-term
eﬀects in this class is derived from cohort studies on co-
caine-exposed children. While there has been a longitudinal
cohort study of children exposed to amphetamines in utero
[26], long-term studies on children exposed to speciﬁcally
methamphetamine are underway, but it is not yet known if
there will be signiﬁcant diﬀerences in long-term outcome.
Inappropriate use of prescription pain medications (nar-
cotics) and benzodiazepines are included as illicit drug usage
[34].
Beyond the possible short- and long-term health eﬀects,
concern for the welfare and safety of newborns exposed to
illicit drugs in pregnancy exists due to the cooccurring pro-
blems that many women with substance abuse disorders
struggle with including undiagnosed/undertreated mental
health issues, intergenerational addiction disorders within
the family support system, and involvement in relationships
with interpersonal violence [35–38]. The Adverse Childhood
Experiences study group has shown that as the frequency of
interpersonalviolenceincreasesinachild’shome,sodoesthe
risk of becoming a victim of child abuse [39].
All newborns exposed to illicit drugs during pregnancy
will not have adverse short- or long-term health eﬀects, and
the identiﬁcation of a mother with a substance abuse dis-
order does not automatically infer the child will become a
victimofabuseorneglect[40,41].Theadequacyofthehome
environment is a strong factor in neurodevelopmental out-
come [21, 23, 42] further highlighting the need to use iden-
tiﬁcation of a newborn exposed to illicit drugs in pregnancy
as an opportunity to be aware of problems that may manifest
in the delivery room or nursery and assess the safety of the
newborn’shomeenvironmenttobealongwiththepsychoso-
cial situation of the family for needed supportive services
[15].
3. Drug Testing in Newborns
In 2003, the United States Congress amended the Child
Abuse Prevention and Treatment Act (CAPTA) by passing
the Keeping Children and Families Safe Act. With this amend-
ment, lawmakers conditioned a state’s receipt of federal
CAPTAfundsontheestablishmentofproceduresbythestate
to develop a plan of safe care when newborns exposed to
illicitsubstancesduringpregnancyarereportedbyhealthcare
providers [43]. However, the Act leaves the decision on who
should be tested to the healthcare provider. To avoid bias
in testing towards newborns of women from poverty or
minority backgrounds where substance abuse is sometimes
assumed to be more of a problem, objective protocols for
recognition of which newborns should be tested can be im-
plemented [44–46]. The guideline from the authors’ institu-
tion which was compiled from a previously published evi-
denced-based approach that identiﬁed maternal and new-
bornfactorsassociatedwithillicitdrugusage[43]andsubse-
quently vetted with perinatal staﬀ at the authors’ institution
is available in Table 2. The authors provide their guidelines
and discussion and are not making a recommendation for
adoption of what has been established at their institution as
a universal standard.
Each healthcare facility should develop its own policy to
addressissuesofconsentinnewborndrugtesting.Theintent
of the test must be clearly deﬁned. Testing for the pur-
pose of guiding healthcare and followup after discharge may
be covered on the general consent to treatment for the fa-
cility [47], whereasin the United States, testing for illicit sub-
stances in the absence of medical indications may be dis-
linebreak criminatory and violate the patient’s civil rights
[48].
The healthcare provider has the responsibility to differ-
entiate between screening and conﬁrmatory drug testing re-
sults. This is especially true in cases in which a newborn
has tested positive for an illicit drug and the mother has not
admitted to usage. The potential for false positive testing by
immunoassay screening should be acknowledged [49]a n d
investigated further by ordering a direct identiﬁcation, con-
ﬁrmation method such as gas chromatography-mass spec-
troscopy [44, 50]. The rate of false-positive immunoassay
screening is particularly crucial with amphetamines and
benzodiazepines [49].
Testing in newborns can be performed on urine, blood,
meconium, hair, or umbilical cord blood or tissue samples.
Immunoassay screening of urine and blood provide the most
rapid results with urine usually preferred due to availa-
bility through noninvasive bag specimen collection. Drugs
will clear rapidly from urine making false negative results
possible when there is a delay in collection [8, 51, 52]. A lab-
oratory’s use of workplace standards for drug detection as
opposed to lowest detectable limits can also lead to false
negative screening results [44].
Meconium formation begins in 2nd trimester, and pos-
itive results typically reﬂect exposure in the last month or
longer prior to delivery [44, 52]. Tests of meconium will
more accurately identify a history of drug use rather than
immediate drug use and are often more accurate than urine
due to collection issues [3, 51]. First time drug usage just
beforedeliverymayresultinafalsenegativemeconiumasthe
drug may not have had time for deposition. Therefore, urine
testing may still be needed to cover the possible time periods
of exposure prior to delivery. Results may not be available
for several days after collection as meconium specimensInternational Journal of Pediatrics 3
Table 1: Possible eﬀects on newborns due to illicit drug use in pregnancy (not a complete list).
Drug Possible eﬀects on the newborn
Stimulants: Perinatal:
Methamphetamine,
Cocaine....
Low birth weight [10–12]
CNS irritability/lability of state [13–15]
—crying, jittery, sleep/wake alterations may have continued exposure through breastfeeding
Neurodevelopmental alterations [16]
Necrotizing enterocolitis [17]
(Teratogenicity suggested by case studies but not conﬁrmed by larger cohort or animal studies)
[18]
Long term:
Modest but measurable longitudinal diﬀerences of cocaine-exposed infants in growth [19, 20],
cognition [21], language [22], and impaired behavioral self-regulation [23, 24]. Other risk and
protective factors can moderate outcome [23–25].
Longitudinal cohort of amphetamine-exposed infants showed school and behavioral problems
(but environment impacts as well) [26].
Longitudinal methamphetamine studies are underway [27].
Opiates/Opioids: Perinatal:
Heroin, morphine, codeine,
oxycodone, hydrocodone,
meperidine, fentanyl, (and
others)
Low birth weight [8, 9]
Neonatal Abstinence Syndrome (NAS) [15, 28] scoring system available:
(i) CNS irritability
(ii) Autonomic dysfunction
(iii) Respiratory symptoms
(iv) GI disturbances
Long term:
Longitudinal studies limited, problems with behavioral self-regulation reported [27].
Cannabinoids: Perinatal:
Marijuana
Low birth weight with heavy exposure [29]
Lability of state [15]
Long term:
Impulsivity [8] and eﬀects on executive functioning later in life [8, 30]
Hallucinogens: Perinatal:
PCP, MDMA, LSD
Low birth weight [7, 8, 13]
CNS irritability [13]
Neurodevelopmental alterations [31]
Long term:
Longitudinal studies not available
Sedatives: Perinatal:
Benzodiazepines,
barbiturates
Low birth weight [32]
Respiratory depression, Hypotonia [33]
Long term:
Longitudinal studies not available
Table 2: Sample guideline for newborn drug testing.
Medical indications for NEWBORN drug testing for possible exposure to illicit drugs
University of Arkansas for Medical Sciences, ANGELS Neonatal Guidelines [46]
(1) History of maternal drug use or agitated/altered mental status in the mother
(2) No prenatal care
(3) Unexplained placental abruption
(4) Unexplained CNS complications in the newborn (seizures, intracranial hemorrhage)
(5) Symptoms of drug withdrawal in the newborn (tachypnea, hypertonicity, excessive stooling/secretions)
(6) Changes in behavioral state of the newborn (jittery, fussy, lethargic)4 International Journal of Pediatrics
Major opiates/opioids
Naturally occurring
• Codeine
-Tylenol no.2/3
• Morphine
Semisynthetic opioids
• Heroin
• Hydrocodone
• Hydromorphone
-Dilaudid
• Oxycodone
• Oxymorphone
∗Trade names are listed for example only and do not
represent a complete list of products in the class∗
-Vicodin, Lortab, Lorcet,
-Tylox, Percodan, OxyContin
Figure 1: High morphine can show up with some hydromorphone,
but generally hydro will break to hydro and oxy to oxy. Codeine
can go to morphine and hydrocodone (not a metabolite of other
opiates). Heroin breaks down to morphine and 6MAM. Codones
canbreaktomorhponesbutnotbackwards.Hydrocodonecangoto
hydrocodol (= dihydrocodeine) and hydromorphone. Hydromor-
phone can go to hydromorphol (same for oxy but separate).
that screen positive for drugs are typically conﬁrmed by a
direct identiﬁcation method in a reference laboratory that
performs such testing. While meconium results oﬀer a wider
window of exposure and more routine usage of conﬁrmatory
methods [53], it is not possible to clearly distinguish when
in the last several weeks-months exposure occurred, and
specimen collection can be diﬃcult in newborns who have
passed meconium in utero prior to delivery and in those who
are very small/critically ill.
Neonatal hair growth begins in the third trimester [44,
52] .W h i l en o ta l ln e w b o r n sw i l lh a v es u ﬃcient hair growth
to allow for adequate specimen collection, hair drug testing
may be helpful if meconium is not available due to transition
to neonatal stool or clinical condition of the baby [52, 54].
Testing of the umbilical cord for in utero drug exposure is an
alternative to meconium collection [55], but it is diﬃcult to
know how far back into pregnancy exposure would produce
a positive test.
Clinicians in the nursery may be asked if it is reasonable
that second hand smoke inhalation by the mother resulted
in a positive newborn drug test. Passive exposure to heavy
amounts of second-hand marijuana or crack cocaine smoke
can result in a positive drug test in an exposed adult, but
low levels of second-hand smoke exposure do not typically
result in positive drug tests [56, 57]. If a mother is in an
environment with others using drugs to the point that it is
causing the mother and her newborn to test positive from
passive exposure, the same concerns about home stability
and cooccurring psychosocial risk factors should be commu-
nicated to personnel assessing the mother’s situation since
the newborn would be exposed to the same environment at
discharge.
Conﬁrmatory drug testing results may report either the
parent drug and/or its metabolites. Therefore, the clinician
should be familiar with basic drug metabolism of commonly
abused drugs in order to account for exposure to certain
Synthetic opioids
( piate-like actions)
Meperidine
-Demerol
•
•
Methadone
• Propoxyphene
-Darvocet
• Tramadol
-Ultram
• Fentanyl
-Duragesic
M a yo rm a yn o tb e
included on
immunoassay drug
screen depending on
local laboratory
practices (speciﬁed on
report separate from
“o
o
piates” if included)
∗This is not a complete list of synthetic opioids∗
Figure 2
parent compounds by the metabolites being detected during
testing instead of the parent drug. In the stimulant class of
drugs, methamphetamine is metabolized to amphetamine
by the liver, but prescription amphetamine compounds will
not metabolize to methamphetamine. Cocaine can metab-
olize to benzoylecgonine, norcocaine, ecgonine methyl ester
(methylecgonine from crack), and if coingested with alcohol,
cocaethylene [58]. Clinicians with questions about the con-
sistency of clinical history with drug test results should con-
sider consultation with a scientist from the reference labo-
ratory that performed the conﬁrmatory testing for the clini-
cian’s facility.
The opiate/opioid class of medications can be one of the
most complex in regards to interpreting drug testing results
[59].Thesemedicationsmaybeusedlegitimatelyformedical
management of labor and delivery pain in the mother,
neonatal pain after delivery, chronic medical conditions in
the mother, and in addiction rehabilitation programs. Pos-
itive opiate results (morphine) can also be observed due to
dietary intake of poppy seed containing foods although con-
ﬁrmation and quantitation of morphine will generally reveal
urinary levels less than 800ng/mL. However, they are also
one of the most commonly inappropriately used/abused
classes of prescription medications. Consultation with clin-
ical toxicology experts is recommended to fully explore the
interpretation of positive opiate results. Figure 1 shows the
division of this group of medications into primary opiates,
semisynthetic opioids, and synthetic opioids with listing of
common metabolites. It is important for the clinician in the
nursery to understand that the synthetic opioids such as
fentanylormethadonewouldnotbedetectedonroutinetox-
icology screen for opiates. Speciﬁc testing would be required
so their usage during labor and delivery or post delivery for
pain managementwould not accountfora positive screening
t e s tf o ro p i a t e sa si so f t e na s s u m e d( s e eFigure 2).
4. Beyond the Nursery
As part of discharge planning, all newborns exposed to illicit
drugs in pregnancy should have a primary care provider spe-
cifically designated to allow ﬂow of information on risk sta-
tus, referrals, and followup [60]. Caregivers with a substanceInternational Journal of Pediatrics 5
abuse disorder are more likely to perceive care of a child as
stressful and miss well-child visits [61]. Early intervention
servicesshouldbeconsideredbecausetheycanpositivelyim-
pact drug-exposed newborns at risk for developmental delay
[62]. Nurse home visitation may be an appropriate referral
in select cases [63]. Such programs may aid in reduction
of subsequent encounters for ingestions, injuries, and mal-
treatment compared to controls [63, 64], or behavioral pro-
blems in children and in parental distress [65]. Perinatal
healthcare providers should work collaboratively to educate
state legislators that identiﬁcation of drug use alone is not
adequateto address the problems related to pregnant women
with substance abuse disorders. States must develop a plan
to assess families at risk by providing supportive services
through their child welfare departments and include access
to evidence-based substance abuse treatment programs. Pro-
viders should advocate for appropriate funding in child wel-
fare budgets to ensure manageable case loads and staﬀ train-
ing time. Prevention and family preservation instead of pun-
ishment will beneﬁt the state in the long term by decreasing
many of the other public health expenditures related to un-
treated substance abuse disorders.
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